#USA #New York #Lucid Diagnostics #EsoGuard #PAVmed

Lucid Diagnostics to Participate in Canaccord Genuity MedTech Forum

Lucid Diagnostics Inc. (NASDAQ: LUCD), recognized for its innovative approaches in cancer prevention diagnostics, is gearing up for participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum set to take place on November 20, 2025, in the vibrant setting of New York City. This significant event in the MedTech space will not only showcase advancements in medical technology but also provide a platform for stakeholders to connect and discuss the future of healthcare solutions.

Key Participation Details

During the forum, Dennis McGrath, the Chief Financial Officer of Lucid Diagnostics, will be available for personalized discussions through one-on-one meetings with investors. Individuals interested in exploring Lucid’s cutting-edge solutions or any potential collaboration opportunities are encouraged to coordinate meetings through their Canaccord Genuity representatives.

About Lucid Diagnostics

Lucid is a commercial-stage company dedicated to battling cancer through early detection. It holds a unique position in the medical diagnostics arena thanks to its pioneering technology aimed at identifying patients who are at risk of developing esophageal precancer and cancer, particularly stemming from gastroesophageal reflux disease (GERD).

The company’s flagship product, the EsoGuard® Esophageal DNA Test, utilizes samples obtained through the EsoCheck® Esophageal Cell Collection Device in a brief, noninvasive office procedure. This innovative tool is designed not only to facilitate early detection but to significantly reduce the risks associated with potential cancer development and thus enhance patient outcomes.

Lucid Diagnostics stands out as the first and only company in the commercial space to offer such testing specifically engineered for preventing cancer through widespread, proactive screening of at-risk populations. The implications of this technology are profound, as it allows for timely interventions that could save countless lives.

Industry Context and Future Outlook

Participation in the Canaccord Genuity MedTech Forum solidifies Lucid's commitment to advancing cancer prevention strategies and engaging with investors who share a vision for innovative healthcare solutions. As healthcare continues to evolve, the importance of early detection and preventative measures becomes increasingly vital. Lucid’s initiatives reflect an industry-wide shift towards more personalized and preventative healthcare approaches.

The forum will be a prime opportunity for Lucid Diagnostics to showcase its commitment to innovation and discuss its growth trajectory. Forward-looking statements included in their recent coverage highlight various uncertainties, including market acceptance and regulatory challenges that could affect their operations. However, the company's sustained focus on research, development, and market engagement positions it effectively within this dynamic field.

As the healthcare landscape shifts, Lucid holds a crucial role in the endeavors to improve early detection methods, making strides towards a more robust strategy against cancer, highlighting its dedication to enhancing patient care and overall public health.

For further information about Lucid's groundbreaking products and their parent company, PAVmed Inc., interested parties can visit Lucid Diagnostics and PAVmed respectively.

Conclusion

The upcoming Canaccord Genuity MedTech Forum is not just a networking opportunity for Lucid Diagnostics but also a representation of its innovative spirit in the fight against cancer. By providing tools for early detection, Lucid is not just participating in an industry event but is making significant contributions to the future of healthcare through effective cancer prevention strategies.